136 related articles for article (PubMed ID: 33988304)
21. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
Lionetti M; Barbieri M; Manzoni M; Fabris S; Bandini C; Todoerti K; Nozza F; Rossi D; Musto P; Baldini L; Neri A
Oncotarget; 2016 Apr; 7(16):21353-61. PubMed ID: 26870891
[TBL] [Abstract][Full Text] [Related]
22. Random integration of HTLV-1 provirus: increasing chromosomal instability.
Ohshima K; Ohgami A; Matsuoka M; Etoh K; Utsunomiya A; Makino T; Ishiguro M; Suzumiya J; Kikuchi M
Cancer Lett; 1998 Oct; 132(1-2):203-12. PubMed ID: 10397475
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.
Ishio T; Kumar S; Shimono J; Daenthanasanmak A; Dubois S; Lin Y; Bryant B; Petrus MN; Bachy E; Huang DW; Yang Y; Green PL; Hasegawa H; Maeda M; Goto H; Endo T; Yokota T; Hatanaka KC; Hatanaka Y; Tanaka S; Matsuno Y; Yang Y; Hashino S; Teshima T; Waldmann TA; Staudt LM; Nakagawa M
Blood; 2022 Mar; 139(10):1541-1556. PubMed ID: 34818414
[TBL] [Abstract][Full Text] [Related]
24. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
25. Deep targeted sequencing of
Brieghel C; Kinalis S; Yde CW; Schmidt AY; Jønson L; Andersen MA; da Cunha-Bang C; Pedersen LB; Geisler CH; Nielsen FC; Niemann CU
Haematologica; 2019 Apr; 104(4):789-796. PubMed ID: 30514802
[TBL] [Abstract][Full Text] [Related]
26. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
27. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
[TBL] [Abstract][Full Text] [Related]
28. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
Leung GMK; Zhang C; Ng NKL; Yang N; Lam SSY; Au CH; Chan TL; Ma ESK; Tsui SP; Ip HW; So JCC; Ng MHL; Cheng KCK; Wong KF; Siu LLP; Yip SF; Lin SY; Lau JSM; Luk TH; Lee HKK; Lau CK; Kho B; Kwong YL; Leung AYH
Am J Hematol; 2019 Jun; 94(6):650-657. PubMed ID: 30900772
[TBL] [Abstract][Full Text] [Related]
29. p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells.
Takemoto S; Trovato R; Cereseto A; Nicot C; Kislyakova T; Casareto L; Waldmann T; Torelli G; Franchini G
Blood; 2000 Jun; 95(12):3939-44. PubMed ID: 10845931
[TBL] [Abstract][Full Text] [Related]
30. Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants.
Deben C; Van den Bossche J; Van Der Steen N; Lardon F; Wouters A; de Beeck KO; Hermans C; Jacobs J; Peeters M; Van Camp G; Rolfo C; Deschoolmeester V; Pauwels P
Tumour Biol; 2017 Feb; 39(2):1010428317694327. PubMed ID: 28240049
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
32. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States.
Shah UA; Shah N; Qiao B; Acuna-Villaorduna A; Pradhan K; Adrianzen Herrera D; Sica RA; Shastri A; Mantzaris I; Derman O; Kornblum N; Braunschweig I; Ye BH; Verma A; Janakiram M
Cancer; 2020 Feb; 126(3):567-574. PubMed ID: 31769871
[TBL] [Abstract][Full Text] [Related]
34. PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma.
Chung EY; Mai Y; Shah UA; Wei Y; Ishida E; Kataoka K; Ren X; Pradhan K; Bartholdy B; Wei X; Zou Y; Zhang J; Ogawa S; Steidl U; Zang X; Verma A; Janakiram M; Ye BH
Clin Cancer Res; 2019 Jun; 25(12):3589-3601. PubMed ID: 30862694
[TBL] [Abstract][Full Text] [Related]
35. Implication of HTLV-I infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique, French West Indies).
Agapé P; Copin MC; Cavrois M; Panelatti G; Plumelle Y; Ossondo-Landeau M; Quist D; Grossat N; Gosselin B; Fenaux P; Wattel E
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):394-402. PubMed ID: 10096585
[TBL] [Abstract][Full Text] [Related]
36. Point mutations in TP53 but not in p15(Ink4b) and p16(Ink4a) genes represent poor prognosis factors in acute adult T cell leukemia/lymphoma.
Magalhaes M; Oliveira PD; Bittencourt AL; Farre L
Leuk Lymphoma; 2015; 56(12):3434-6. PubMed ID: 25573202
[No Abstract] [Full Text] [Related]
37. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations.
Fioretos T; Strömbeck B; Sandberg T; Johansson B; Billström R; Borg A; Nilsson PG; Van Den Berghe H; Hagemeijer A; Mitelman F; Höglund M
Blood; 1999 Jul; 94(1):225-32. PubMed ID: 10381517
[TBL] [Abstract][Full Text] [Related]
38. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma.
Yamada Y; Kamihira S
Leuk Lymphoma; 2005 Nov; 46(11):1553-9. PubMed ID: 16236609
[TBL] [Abstract][Full Text] [Related]
40. Impact of
Firtina S; Erbilgin Y; Hatirnaz Ng O; Karaman S; Karakas Z; Celkan TT; Gelen SA; Yildirmak Y; Ozbek U; Sayitoglu M
Scand J Clin Lab Invest; 2023 May; 83(3):187-193. PubMed ID: 37029683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
